Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 09:28am CET

Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

The dispute between the Jordan-based firm, its partner Vectura (>> Vectura Group PLC) and the U.S FDA delays any eventual approval of the generic version of the drug.

Shares of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

Hikma, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business.

In August it had lowered its generics revenue guidance by $50 million to about $620 million citing higher pricing pressures in the industry, having slashed it to $670 million from an initial $800 million last November.

The company, that has been hit by higher price erosion levels than the rest of the industry, has been re-negotiating its contracts with suppliers and third-party vendors to cut costs to try to boost profitability.

"We expect these market conditions to persist in 2018 and are actively pursuing new commercial opportunities and focussing on the execution of our pipeline to help offset continuing price erosion across the industry," it said in a statement.

The company, which cut its full-year guidance in May to the range of $2 billion-$2.1 billion from $2.2 billion, said in August that it expected 2017 revenue to be at the lower end of the range at $2 billion.

Hikma reiterated its 2017 revenue expectations on Thursday.

Earlier this month, Israeli-based Teva Pharmaceutical (>> Teva Pharmaceutical Industries Limited), the world's biggest generics drugmaker, said it would miss 2017 profit forecasts citing falling prices of generics in the U.S. market and weakening sales of its multiple sclerosis drug.

Hikma's lower guidance in May followed a decision by U.S. regulators not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application.

Hikma said it expected the dispute process with the FDA to be completed in the first quarter of 2018.

(Reporting by Justin George Varghese in Bengaluru and Ben Hirschler in London; editing by Jason Neely and Keith Weir)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
11/17 GLAXOSMITHKLINE : 10.4% Potential Upside Indicated by Jefferies International
11/17 GLAXOSMITHKLINE : Wolf Administration Official Continues 'Jobs That Pay' Tour at..
11/16 GLAXOSMITHKLINE : Investigators from GlaxoSmithKline plc Release New Data on Pne..
11/16 GLAXOSMITHKLINE : New Cytokines Findings from GlaxoSmithKline Outlined [Identifi..
11/16 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc Provides New Data on Chronic..
11/16 GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Provide New Insights into Vac..
11/16 GLAXOSMITHKLINE : Data from GlaxoSmithKline Advance Knowledge in Bipolar Disorde..
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/16 GLAXOSMITHKLINE : Trelegy Ellipta EU approval for treatment of COPD
11/16 GLAXOSMITHKLINE : Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains..
More news
News from SeekingAlpha
11/17 YOUR DAILY PHARMA SCOOP : Gilead CAR-T Potential, Egalet Surges, Aerie Launches ..
11/16 Glaxo's inhaled triplet therapy for COPD OK'd in Europe
11/15 WALL STREET BREAKFAST : Order War At The Dubai Airshow
11/14 Glaxo And Pfizer Are Top 'Safer' Dividend Healthcare Gainers For November
11/14 HEALTHCARE DOGFIGHT : GlaxoSmithKline Regains Top By Gains In November As O&M & ..
Financials ( GBP)
Sales 2017 30 089 M
EBIT 2017 8 449 M
Net income 2017 3 716 M
Debt 2017 14 279 M
Yield 2017 6,12%
P/E ratio 2017 18,32
P/E ratio 2018 14,80
EV / Sales 2017 2,61x
EV / Sales 2018 2,57x
Capitalization 64 336 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,7  GBP
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-16.26%85 003
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550